Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...

Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

U.S. stocks on Wednesday slipped, as investors digested a slight acceleration in the Federal Reserve's favorite inflation gauge. Here are some of Wednesday's biggest stock movers: Biggest stock ...

Sarepta announced a $1 billion-plus global license and collaboration deal with Arrowhead Pharmaceuticals for multiple ...

An increase in research and development (R&D) activities in myotonic dystrophy is expected to drive market growth by ...

The Lebanese Army said it was deploying forces near the Israeli border as a U.S.-backed truce between Israel and Hezbollah militants began to take effect. Hamas is unlikely to compromise in Gaza ...

The Dow Jones rose Wednesday ahead of the Federal Reserve's favored inflation gauge. Nvidia stock extended its recent losses.